Announcements Trials
Browse Landscape

Phase

Phase 2 114Phase 1 66Phase 1/2 44Phase 3 20Phase EARLY_PHASE1 6Phase 2/3 4Phase NA 3Phase 4 3

Status

Terminated 2Completed 2Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 6

Study Type

Interventional 6

Sponsor

Cancer Type

Dermatologic 6Genitourinary 3Sarcoma 1Head & Neck 1CNS 1

Conditions

Melanoma 5Uveal Melanoma 1Skin Neoplasms 1Motor Activity 1Carcinoma, Merkel Cell 1Brain Neoplasms 1

Interventions

Nivolumab 10pembrolizumab 6Ipilimumab 6Niacinamide 3Magnetic Resonance Spectroscopy 3Itraconazole 3Cyclophosphamide 3Biopsy 3resiquimod 2encorafenib 2durvalumab 2calcipotriene 2binimetinib 2aldesleukin 2Radiotherapy 2Oncolytic Virotherapy 2Niacin 2MART-1 Antigen 2Interleukin-2 2Imiquimod 2HhAntag691 2Fluorouracil 2Ascorbic Acid 2urelumab 1tremelimumab 1tetraethylpyrazine 1technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 1relatlimab 1montanide ISA 51 1glucopyranosyl lipid-A 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Ipilimumab × Dermatologic × Clear all
NCT05498792 2026-05-22

Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma

Fox Chase Cancer Center

Phase EARLY_PHASE1 Recruiting
12 enrolled
Dermatologic

Melanoma

NCT05704933 2026-04-06

Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases

H. Lee Moffitt Cancer Center and Research Institute

Phase EARLY_PHASE1 Completed
1 enrolled
CNSDermatologic

Brain Neoplasms, Melanoma

NCT05358938 2026-02-06

Exercise to Boost Response to Checkpoint Blockade Immunotherapy

H. Lee Moffitt Cancer Center and Research Institute

Phase EARLY_PHASE1 Active not recruiting
22 enrolled
Dermatologic

Melanoma, Motor Activity, Skin Neoplasms, Carcinoma, Merkel Cell

NCT03526185 2022-07-25

A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes

Yale University

Phase EARLY_PHASE1 Terminated
6 enrolled
Dermatologic

Melanoma

NCT00972933 2017-12-07

Immunogenicity and Biomarker Analysis of Neoadjuvant Ipilimumab for Melanoma

University of Pittsburgh

Phase EARLY_PHASE1 Completed
59 enrolled
Dermatologic

Melanoma

NCT01730157 2016-03-10

Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases

Case Comprehensive Cancer Center

Phase EARLY_PHASE1 Terminated
6 enrolled
Dermatologic

Uveal Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡